Mapping the genomic landscape of CRISPR-Cas9 cleavage

被引:0
|
作者
Cameron P. [1 ]
Fuller C.K. [1 ]
Donohoue P.D. [1 ]
Jones B.N. [1 ,3 ]
Thompson M.S. [1 ]
Carter M.M. [1 ]
Gradia S. [1 ]
Vidal B. [1 ]
Garner E. [1 ]
Slorach E.M. [1 ]
Lau E. [1 ]
Banh L.M. [1 ]
Lied A.M. [1 ]
Edwards L.S. [1 ]
Settle A.H. [1 ]
Capurso D. [1 ]
Llaca V. [2 ]
Deschamps S. [2 ]
Cigan M. [2 ,4 ]
Young J.K. [2 ]
May A.P. [1 ,5 ]
机构
[1] Caribou Biosciences, Berkeley, CA
[2] DuPont Pioneer, Johnston, IA
[3] Omicia, Inc., Oakland, CA
[4] Genus Research, DeForest, WI
[5] Chan Zuckerberg Biohub, San Francisco, CA
关键词
D O I
10.1038/nmeth.4284
中图分类号
学科分类号
摘要
RNA-guided CRISPR-Cas9 endonucleases are widely used for genome engineering, but our understanding of Cas9 specificity remains incomplete. Here, we developed a biochemical method (SITE-Seq), using Cas9 programmed with single-guide RNAs (sgRNAs), to identify the sequence of cut sites within genomic DNA. Cells edited with the same Cas9-sgRNA complexes are then assayed for mutations at each cut site using amplicon sequencing. We used SITE-Seq to examine Cas9 specificity with sgRNAs targeting the human genome. The number of sites identified depended on sgRNA sequence and nuclease concentration. Sites identified at lower concentrations showed a higher propensity for off-target mutations in cells. The list of off-target sites showing activity in cells was influenced by sgRNP delivery, cell type and duration of exposure to the nuclease. Collectively, our results underscore the utility of combining comprehensive biochemical identification of off-target sites with independent cell-based measurements of activity at those sites when assessing nuclease activity and specificity. © 2017 Nature America, Inc. All rights reserved.
引用
收藏
页码:600 / 606
页数:6
相关论文
共 50 条
  • [41] Ethics and Genomic Editing Using the Crispr-Cas9 Technique: Challenges and Conflicts
    Lorenzo, David
    Esquerda, Montse
    Palau, Francesc
    Cambra, Francisco J.
    NANOETHICS, 2022, 16 (03) : 313 - 321
  • [42] Genomic ablation of rhesus macaque VEGFa using CRISPR-Cas9 ribonucleoprotein
    Sin, Tzu-Ni
    Chung, Sook Hyun
    Ngo, Taylor
    Yiu, Glenn
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [43] Ethics and Genomic Editing Using the Crispr-Cas9 Technique: Challenges and Conflicts
    David Lorenzo
    Montse Esquerda
    Francesc Palau
    Francisco J. Cambra
    Grup Investigació en Bioética
    NanoEthics, 2022, 16 : 313 - 321
  • [44] Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9
    Zhang, Yuan
    Karakikes, Ioannis
    TRENDS IN CARDIOVASCULAR MEDICINE, 2021, 31 (06) : 341 - 348
  • [45] CRISPR-Cas9 enrichment and long read sequencing for fine mapping in plants
    Lopez-Girona, Elena
    Davy, Marcus W.
    Albert, Nick W.
    Hilario, Elena
    Smart, Maia E. M.
    Kirk, Chris
    Thomson, Susan J.
    Chagne, David
    PLANT METHODS, 2020, 16 (01)
  • [46] Frequent Aneuploidy in Primary Human T Cells after CRISPR-Cas9 Cleavage
    Nahmad, Alessio D.
    Reuveni, Eli
    Ella, Goldschmidt
    Asaf, Madi
    Ben David, Uri
    Barzel, Adi
    MOLECULAR THERAPY, 2023, 31 (04) : 402 - 402
  • [47] Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage
    Nahmad, Alessio David
    Reuveni, Eli
    Goldschmidt, Ella
    Tenne, Tamar
    Liberman, Meytal
    Horovitz-Fried, Miriam
    Khosravi, Rami
    Kobo, Hila
    Reinstein, Eyal
    Madi, Asaf
    Ben-David, Uri
    Barzel, Adi
    NATURE BIOTECHNOLOGY, 2022, 40 (12) : 1807 - 1813
  • [48] Heterogeneity of CRISPR-Cas9 binding, cleavage, and DNA damage responses at endogenous loci
    Zou, Roger S.
    Liu, Yang
    Liu, Hans B.
    Marin-Gonzalez, Alberto
    Luo, Jay X. J.
    Ha, Taekjip
    BIOPHYSICAL JOURNAL, 2022, 121 (03) : 23 - 23
  • [49] Computational Analysis Concerning the Impact of DNA Accessibility on CRISPR-Cas9 Cleavage Efficiency
    Chung, Cheng-Han
    Allen, Alexander G.
    Sullivan, Neil T.
    Atkins, Andrew
    Nonnemacher, Michael R.
    Wigdahl, Brian
    Dampier, Will
    MOLECULAR THERAPY, 2020, 28 (01) : 19 - 28
  • [50] Frequent Aneuploidy in Primary Human T Cells Following CRISPR-Cas9 Cleavage
    Nahmad, Alessio D.
    Reuveni, Eli
    Goldschmidt, Ella
    Tenne, Tamar
    Liberman, Meytal
    Horovitz-Fried, Miri
    Khosravi, Rami
    Kobo, Hila
    Reinstein, Eyal
    Madi, Asaf
    Ben-David, Uri
    Barzel, Adi
    MOLECULAR THERAPY, 2022, 30 (04) : 267 - 267